XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Gynae-Oncology Trials

A list of our early phase gynae-oncology trials which are open to recruitment at University College London Hospitals

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

Additional early phase clinical trials recruiting Gynae-Oncology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.

 

PROMPT

Phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer

Local Project Reference:17/0629
Principal Investigator:Prof. Jonathan Ledermann
Drug Class/ Treatment:

Pembrolizumab (PD-1 Inhibitor) + Paclitaxel (Chemotherapy)

Patient Population:
  • Recurrent Ovarian Cancer
  • Recurrent Fallopian Tube Cancer
  • Recurrent Peritoneal Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

BOUQUET (WO42178)

A Phase II, Open-Label, Multicenter, Platform Study Evaluating The Efficacy And Safety Of Biomarker-Driven Therapies In Patients With Persistent Or Recurrent Rare Epithelial Ovarian Tumors

Local Project Reference:139231
Principal Investigator:Dr. Rowan Miller
Drug Class/ Treatment:Platform trial of various Immunotherapy and Targeted Therapy Agents.
Patient Population:Persistent Or Recurrent Rare Epithelial Ovarian Tumors
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

EP0057-201 (Ellipses)

A Phase 2 study of EP0057 and Olaparib in ovarian cancer patients:  A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease; Cohort 2 – had at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance.

Local Project Reference:135878
Principal Investigator:Dr. Rowan Miller
Drug Class/ Treatment:

EP0057 (Nanoparticle-Drug Conjugate Topoisomerase 1 Inhibitor) + Olaparib (PARP Inhibitor)

Patient Population:Ovarian Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)